The clinical activity of afatinib and pembrolizumab observed in select patients highlights that despite the overall lack of activity from PD(L)1 blockade in EGFR-mutated NSCLC, there are potential subsets of patients with EGFR-mutant lung cancer who may benefit from an immunotherapy-based approach. This evidence concerns the gene EGFR and lung cancer.